20th Hemoglobin Switching Conference

第20届血红蛋白转换会议

• 批准号: 9197787
• 负责人: James Douglas Engel
• 金额: $ 5.5万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9197787
• 关键词: American Society of Hematology; Anabolism; Back; Biochemical; Biochemistry; California; Carbon Dioxide; Cell Differentiation process; Cells; Cellular biology; Clinical; Collaborations; Complementary DNA; Development; Developmental Biology; Disease; Epigenetic Process; Erythrocytes; Erythropoietin; Etiology; Europe; Faculty; Family; Fertilization; Gene Expression Regulation; Genetic; Genomics; Globin; Great Britain; Hematology; Hematopoietic; Hemoglobin; Hemoglobinopathies; Hereditary Disease; Human Cloning; Human Genetics; Inherited; International; Lung; Metabolic Diseases; Metabolism; Minority; Molecular; Molecular Biology; Mutation; Oxygen; Participant; Physiology; Postdoctoral Fellow; Process; Research; Research Personnel; Science; Scientist; Site; Structure; Students; Time; Tissues; Woman; Work; abstracting; career; disease phenotype; effective therapy; man; meetings; novel; phenomenological models; success; symposium; transcription factor

Abstract The biennial Hemoglobin Switching Conference has been ongoing for 39 years, and there are multiple reasons for its resounding success. First and foremost, the organizers (Stamatoyannopoulos, Higgs and Engel) strive to identify and then highlight new discoveries by always including new, young investigators and studies that impinge on the process of globin biosynthesis. Second, this is the only venue (other than the annual ASH meeting, with more than 14,000 participants) that brings together basic scientists and clinicians to discuss both the molecular and developmental origins of, and treatments for, the hemoglobinopathies, the most common inherited diseases in man. Third, the meetings have historically evolved with intense focus on wherever the science led, thus remaining extremely topical, and has not only been the forum for presenting the first cDNA clones, the first cloned human genomic locus (and the first mutations in same), the structure of erythropoietin and the discovery of the GATA and KLF transcription factor families, but it has also launched the careers of many of the current leaders in this field (indeed, numerous postdoctoral fellows and young faculty first presented their work in plenary sessions at this conference). Fourth, this is the only meeting on this topic that routinely has approximately equal attendance by investigators from both inside and outside the U.S., and this fact is reflected by the biennial alternation in site between the U.S. and Europe. In 2016 the Conference will be held for the third time at the Asilomar Conference Center in California, because of both the ease of international accessibility and economy.

抽象的 双年展的血红蛋白转换会议已经进行了39年，并且有 取得成功的多种原因。首先，组织者（Stamatoyannopoulos， 希格斯（Higgs）和恩格尔 研究的人和研究构成球蛋白生物合成过程。第二，这是唯一的 场地（除了年度ASH会议，有14,000多名参与者）聚集在一起 基础科学家和临床医生讨论分子和发育起源的 血红蛋白病的治疗方法，是人类中最常见的遗传疾病。第三， 在历史上，会议一直在演变为科学所在的任何地方，因此仍在 极其主题，不仅是展示第一个cDNA克隆的论坛，也是第一个克隆的论坛 人类基因组基因座（以及第一个突变），促红细胞生成素的结构和 发现GATA和KLF转录因子家庭，但也启动了职业生涯 该领域的许多目前领导人（实际上，有许多博士后研究员和年轻教师首先 在本次会议上介绍了他们在全体会议上的工作）。第四，这是唯一的会议 从内部和外部的调查员通常在常规上具有平等出勤率的主题 美国，这一事实反映了美国和欧洲之间的两年一次的交替。在 2016年会议将第三次在加利福尼亚的Asilomar会议中心举行 由于国际可及性和经济的便利性。